1. Signaling Pathways
  2. Immunology/Inflammation
  3. AP-1

AP-1

Activator Protein 1 (AP-1) is not a single protein, but a collective term referring to dimeric transcription factors composed of Jun (c-Jun, JunB, JunD), Fos (c-Fos, FosB, Fra-1, Fra-2) ATF (activating transcription factor, ATF-2, ATF-3/LRF1, ATF-4, ATF-5, ATF-6B, ATF-7, BATF, BATF-2, BATF-3, JDP2) or MAF (c-MAF, MafA, MafB, MafF, MafG, MafK and Nrl) subunits that bind to a common DNA site, the AP-1-binding site. AP-1 is involved in a plethora of cellular and physiological functions. It is acknowledged as a master integrator of a myriad of extracellular signals allowing cells to adapt to changes in their environment. AP-1 has also been implicated in various severe diseases. These include transplant rejection, fibrosis, organ injury and a variety of inflammatory pathologies such as rheumatoid arthritis, asthma and psoriasis. In addition, cancer is undoubtedly the most documented pathology involving AP-1 where its activity is often dysregulated and contributes to cell transformation, tumor progression, aggressiveness and resistance to treatments.

AP-1 Related Products (3):

Cat. No. Product Name Effect Purity
  • HY-12270
    T-5224
    Inhibitor 99.59%
    T-5224 is a transcription factor c-Fos/activator protein (AP)-1 inhibitor with anti-inflammatory effects, which specifically inhibits the DNA binding activity of c-Fos/c-Jun without affecting other transcription factors. T-5224 inhibits the IL-1β-induced up-regulation of Mmp-3, Mmp-13 and Adamts-5 transcription.
  • HY-19357
    E3330
    Inhibitor 98.01%
    E3330 (APX-3330) is a direct, orally active and selective inhibitor of Ape-1 (apurinic/apyrimidinic endonuclease 1)/Ref-1 (redox factor-1) redox. E3330 is able to impair tumor growth and blocks the activity of NF-κB, AP-1, and HIF-1α in pancreatic cancer. E3330 shows anticancer activities.
  • HY-141645
    IMM-H007
    Inhibitor
    IMM-H007 (WS070117) is an orally active and potent AMPK (AMP-activated protein kinase) activator and TGFβ1 (transforming growth factor β1) antagonist. IMM-H007 has protective effects in cardiovascular diseases via activation of AMPK. IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. IMM-H007 inhibits ABCA1 degradation. IMM-H007 resolves hepatic steatosis in HFD-fed hamsters by the regulation of lipid metabolism. IMM-H007 can be used for the research of nonalcoholic fatty liver disease (NAFLD) and inflammatory atherosclerosis.